| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
King Faisal Specialist Hospital & Research Center |
| Information provided by: | King Faisal Specialist Hospital & Research Center |
| ClinicalTrials.gov Identifier: | NCT00535509 |
Purpose
Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer
| Condition | Intervention |
|
Breast Cancer |
Radiation: Cisplatin-Docetaxel ± Trastuzumab Other: Cisplatin-Docetaxel ± Trastuzumab Drug: Cisplatin-Docetaxel ± Trastuzumab |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer |
| ChemIDplus related topics: | Docetaxel Cisplatin Trastuzumab |
| Study Type: | Interventional |
| Study Design: | Open Label, Single Group Assignment |
Eligibility
| Genders Eligible for Study: | Female |
Inclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | RAC #2061-048 |
| First Received: | September 24, 2007 |
| Last Updated: | September 24, 2007 |
| ClinicalTrials.gov Identifier: | NCT00535509 |
| Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
